Pfizer's stock is poised for growth due to its strong pipeline, smart cost management, and recovery from COVID-19 revenue ...

The company is actively running Phase 3 trials for atirmociclib in breast cancer, sigvotatug vedotin in lung cancer, and candida in head and neck and lung cancers. These trials aim to expand ...

The company is aggressively expanding its oncology pipeline with ongoing Phase 3 trials for sigvotatug vedotin in lung cancer and planned studies in other cancers. A Phase 3 readout for multiple ...

Among the new phase 3 starts are CDK4 inhibitor atirmociclib as a second-line therapy for hormone receptor-positive metastatic breast cancer, IB6-directed ADC sigvotatug vedotin for non-small cell ...

We recently published a list of 10 Most Profitable Value Stocks to Buy Now. In this article, we are going to take a look at ...

The company is aggressively expanding its oncology pipeline with ongoing Phase 3 trials for sigvotatug vedotin in lung cancer ...

The company’s oncology pipeline includes several promising trials, such as atirmociclib for breast cancer and sigvotatug vedotin for lung cancer. Pfizer is expecting significant Phase 3 trial results ...

Pfizer (NYSE:PFE) is undervalued, trading well below its historical and sector averages despite strong non-COVID revenue growth and cost optimizations. Its expanding pipeline in oncology, obesity ...